New, Patented FlexAgility(TM) Debuts as Unique Ginger Product Clinically Proven to Reduce Joint Pain From Occasional Overuse

GREEN BAY, Wis., June 12 -- Enzymatic Therapy introduces a proprietary herbal extract containing ginger (Zingiber officinale) and greater galangal (Alpinia galanga) clinically proven to reduce pain and stiffness due to occasional overuse. The patented blend, whose effectiveness is backed by clinical studies, is the only ginger and greater galangal product of its kind in the U.S.

The journal Arthritis and Rheumatism recently published a double-blind, placebo-controlled multicenter study that examined the effect of FlexAgility in humans. A total of 247 study participants were evaluated at week two of the study and again at the conclusion of the study on week six. The overall results demonstrated that at both evaluation periods, the FlexAgility group experienced superior joint support compared to the placebo group.

FlexAgility is a patented herbal extract in a form that provides enhanced bioavailability and stability. It contains EV.EXT(R) 77, a proprietary blend of ginger and greater galangal. Pharmacokinetic studies indicate that the patented form is responsible for the herbal blend's effectiveness.

Part of this effectiveness is FlexAgility's ability to reduce pain from occasional overuse without causing gastrointestinal side effects. The combination formula inhibits the enzymes that cause pain and stiffness, yet does not significantly interfere with the important enzymes that protect the stomach lining.

Ginger and ginger extracts are known to reduce stiffness due to occasional overuse. Certain compounds in ginger are believed to be responsible for inhibition of particular enzymes associated with joint pain and stiffness due to occasional overuse. Alpinia galanga, also known as greater galangal has constituents comparable to, but not the same as, ginger, hence the compound's effectiveness. Several studies have examined its various properties, including research that demonstrates its ability to effectively manage nitric oxide production, and activate protein kinase C. Protein kinase C supports cartilage health under mechanical stress.

FlexAgility(TM) is available in 60-count bottles of softgels that retail for $21.95.

Enzymatic Therapy is a leader in nutritional joint health products having been the first company to introduce glucosamine sulfate to the U.S. health market in 1993. The company manufactures and distributes over 200 natural medicines, nutritional supplements, vitamins and herbal extracts. Enzymatic Therapy was also the first to introduce Ginkgo biloba and the standardization of botanicals to the United States health market. All Enzymatic Therapy formulations are lab-tested for purity, potency and bioavailability, and the company distributes its extensively researched product line to health food stores nationwide.

SOURCE Enzymatic Therapy

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.